Table 1.

Demographic of the patients and probes selected in the assay.

Patient #	Age at Tx.	Gender	Disease	HLA mismatch (A, B, DR)	Recipient HLA-DR	Donor HLA-DR	Probe Target (Reci/Donor)	# of samples
1	42	M	ILD	2--2--2	03, 15	01,04	03, 01	3
2	52	M	IPF	1--2--2	04,13	07,13	04, 07	4
3	45	F	COPD	1--1--1	04,14	01,04	04, 01	5
4	59	F	IPF	2--2--2	04,08	07,12	04, 07	3
5	57	F	COPD	2--2--2	12,15	11,14	15, 11	4
6	69	M	IPF	2--2--2	04,14	01,13	04, 13	3
7	66	M	IPF	0--2--1	04,15	04,13	15, 13	2
8	50	M	A1AD	1--2--2	04,07	04,11	07, 11	3
9	22	F	CF	2--2--2	01,04	01,07	04, 07	5
10	62	M	COPD	1--2--1	03,13	11,13	03, 11	5
11	62	F	IPF	2--2--1	03,04	04,07	03, 07	3
12	66	F	IPF	1--2--1	11,13	03,04	11, 04	4
13	39	F	MCTD	2--2--1	07,07	07,11	07, 11	2
14	56	M	IPF	2--2--2	07,16	03,15	07, 03	2
15	57	M	IPF	1--1--2	04, 13	07,11	13, 07	2
16	53	M	IPF	2--1--2	04,15	03,08	15, 08	5
17	70	M	ILD	2--2--1	15,16	13,15	15, 13	5
18	68	M	COPD	2--1--2	01,03	11,15	01, 11	2

A1AD: Alpha 1-antitrypsin deficiency; MCTD: Mixed connective tissue disease; CF: Cystic fibrosis; ILD: Interstitial lung disease; IPF: Idiopathic pulmonary fibrosis; COPD: Chronic obstructive pulmonary disease. Patient 1–7 are stable patients. 8–12 are BOS positive patients and 13–18 are rejection patients.